Navigation Links
Heart Disease Treatment Breakthrough
Date:6/1/2009

GATESHEAD, England, June 1 /PRNewswire/ -- A leading GP has welcomed the launch of a potentially revolutionary heart disease treatment that offers people around the world the hope of combating the killer disease.

GP Dr Rob Hicks said the launch of Ateronon, the natural supplement developed by Cambridge scientists, was a huge breakthrough in the treatment of heart disease related illnesses that can cause heart attacks and stroke.

Dozens of research studies have shown that lycopene - found in the skins of ripe tomatoes - has the capacity to significantly reduce the build up of plaque in the arteries that can lead to heart attacks and stroke.

Lycopene is the potent antioxidant isolated for its health-promoting properties from the Mediterranean diet (http://www.ateronon.com/).

Until now, scientists have been unable to find a way of modifying lycopene molecules so they can be readily absorbed into the human body.

Researchers from Cambridge Theranostics Limited (CTL), a biotech spin-out company of Cambridge University, have now proved they have done it with their new Ateronon compound.

Dr Hicks said: "If you think that this can reduce the damage to the arteries, which is the damage that ends up causing heart attacks and strokes - this can potentially extend life but also saving lives on a global basis.

"The potential impact is enormous - we might see a fall in the number of people suffering heart attacks, strokes and other problems relating to arterial damage and the clogging up of the arteries. That has to be welcomed," he added.

Results from their early trials involving 150 people with heart disease were made public for the first time at the British Cardiovascular Society annual conference in London on Monday (1st June).

The Ateronon formulation combines lycopene with milk and soy-based proteins to produce a much smaller, and more bio-available molecule. The early studies have shown that Ateronon can inhibit the oxidation of low density lipoprotein (LDL) cholesterol, which can put people at risk of suffereing heart attacks and stroke, to almost zero within eight weeks.

An estimated 17.5 million people died from heart and circulatory diseases in 2005, representing 30% of all global deaths. Of these deaths, an estimated 7.6 million were due to coronary heart disease and 5.7 million were due to stroke[1].

More than 117,000 people die each year in the UK from coronary heart disease. It accounts for one in five deaths in men and one in six deaths in women[2].

The four million people who take statins to help lower their cholesterol and chances of suffering a heart attack or stroke could benefit from using Ateronon. The product can be taken alongside statins.

Although cholesterol does put people at risk of suffering a heart attack or stroke, half of all heart attacks and three quarters of all strokes occur in people who do not have raised cholesterol.

Large scale studies of Ateronon are being undertaken at Addenbrookes Hospital, Cambridge, and at Harvard Medical School, in the expectation that they will demonstrate that the reduction of LDL oxidation is translated into improved heart and circulatory health - and improved survival rates.

The study was built on research originally carried out by the multi-national food giant Nestle, who were looking for a way to capture the therapeutic benefits of the tomato-derived compound lycopene.

After its launch to doctors this month, Ateronon will be made available direct to consumers through high street pharmacists from July onwards.

Dr Gunter Schmidt, a biologist and chief executive of CTL, said he was confident that once doctors had observed the benefits of Ateronon, they would instantly see the potential benefits.

He said: "We are extremely excited about Ateronon. We have 10 worldwide patents recognising its efficacy, but we want its capabilities to be taken very seriously by clinicians as well. We don't want it dismissed as just another food supplement."

For further information go to http://www.ateronon.com or http://www.youtube.com/watch?v=uJjcpnCHOxI

---------------------------------

[1] World Health Organization

[2] British Heart Foundation

For further information, please contact Helen Barklam at Custard Media, tel: +44(0)1772-316924 or +44(0)7917-148900 or email helen@avaandgrace.com.


'/>"/>
SOURCE Ateronon.com
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Many Heart Attack Patients Dont Get Best Emergency Treatment
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
4. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
5. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
6. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
7. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
8. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
9. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
10. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
11. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
Breaking Medicine Technology:
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):